Botanix Pharmaceuticals reports stronger Sofdra revenue. Supply, tariffs, cash and patents are the next themes for the dermatology group.
What Is Next for Botanix (ASX:BOT) as Sofdra Revenue Builds? - Kalkine Media
Botanix Pharmaceuticals reports stronger Sofdra revenue. Supply, tariffs, cash and patents are the next themes for the dermatology group.